Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Role of Tips in Acute Variceal Bleeding

  • Huerta, Anna|||0000-0002-2524-770X
  • García-Guix, Marta
  • Villanueva, Càndid|||0000-0002-3674-914X
Purpose of review: We aimed to review the role of TIPS in acute variceal bleeding (AVB), focusing on preemptive-TIPS (p-TIPS) as discrepant data suggest room for refinement. Recent findings: Salvage-TIPS can effectively control ongoing AVB despite first-line therapy, but mortality is high. Placing a p-TIPS to prevent failure in high-risk patients may improve survival. This is related to its effect decreasing the overall risk of a further decompensation (FD), not just rebleeding but also ascites and derived complications. Summary: FD is closely related to death risk after AVB. The risk of FD and death concentrates in patients presenting with ascites ± HE in addition to AVB. p-TIPS improve survival, not only by decreasing rebleeding risk, but mainly FD overall. This review suggests potential improvements to optimize p-TIPS, such as improving risk stratification, restricting the indication to patients with AVB and ascites ± HE, or selectively identifying those at high-risk of failure (10%-15% cases) for an early placement. Research on these issues is warranted.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals

  • Pons Delgado, Mònica|||0000-0002-0985-3320
  • Santos, Begoña
  • Simón Talero, Macarena|||0000-0002-1409-3936
  • Ventura-Cots, Meritxell|||0000-0001-9513-2855
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Esteban, Rafael|||0000-0001-5280-392X
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
We aimed to investigate the early changes in liver and spleen stiffness measurement (LSM, SSM) in hepatitis C virus (HCV) patients with compensated advanced chronic liver disease (cACLD) treated with new antivirals (DAA) to elucidate factors determining the initial change in stiffness and its implications for the long-term follow up of HCV-cured patients. A total of 41 patients with cACLD who started DAA therapy underwent LSM and SSM at baseline, week 4, end of treatment (EOT), 24 and 48 weeks of follow up using transient elastography. LSM improved rapidly during the first 4 weeks of treatment (baseline: 20.8kPa; week 4: 17.5kPa, p = 0.002), with no significant changes between week 4 and EOT (18.3kPa, p = 0.444) and between EOT and 48-week follow up (14.3kPa, p = 0.148). Likewise, SSM improved rapidly (baseline: 45.7kPa; week 4: 33.8kPa, p = 0.047), with no significant changes between week 4 and EOT (30.8kPa, p = 0.153) and between EOT and 48-week follow up (31.2kPa, p = 0.317). A higher decrease in LSM was observed in patients with baseline ALT ⩾ twofold upper limit normal (2 × ULN) than in those with ALT < 2 × ULN (-5.7kPa versus -1.6kPa). Patients who presented a decrease in LSM ⩾ 10% during treatment compared with those with LSM < 10% decrease, showed lower SSM values, higher platelet counts and lower bilirubin levels at 24-week follow up. Those with decrease in SSM ⩾ 10%, presented a higher increase in platelets than those with SSM < 10% change (p = 0.015). LSM and SSM decrease very rapidly during DAA treatment in cACLD patients suggesting that it most probably reflects a reduction in inflammation rather than in fibrosis. cACLD patients should be maintained under surveillance independently of stiffness changes, because advanced fibrosis can still be present.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients

  • Ventura-Cots, Meritxell|||0000-0001-9513-2855
  • Carmona, Isabel
  • Moreno, Carol|||0000-0003-3275-0271
  • Ampuero, Javier|||0000-0002-8332-2122
  • Simón Talero, Macarena|||0000-0002-1409-3936
  • Sanpedro, Francesc
  • Les, Iñigo
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
Episodes of hepatic encephalopathy (HE) have been related to low survival rate. However, the relation between its clinical evolution and mortality has not been assessed. A retrospective analysis of 245 cirrhotic patients admitted for an acute episode of HE (⩾grade 2) or who developed an HE episode after an upper gastrointestinal bleeding (UGIB) event was performed to assess the relation between time in HE and transplant-free survival. Median (IQR) time in HE was 48 h (24-96 h) in the whole cohort. Patients who presented a longer time in HE (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH

  • Bravo, Miren|||0000-0001-5889-9125
  • Raurell, Imma|||0000-0003-4477-7367
  • Hide, Diana
  • Fernández-Iglesias, Anabel|||0000-0003-2364-6675
  • Gil, Mar
  • Barberá Bellés, Aurora|||0000-0002-6201-2643
  • Salcedo, Maria-Teresa|||0000-0002-4822-5060
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
  • Martell, María|||0000-0002-0935-0029
Non-alcoholic steatohepatitis (NASH) is a common chronic liver disorder in developed countries, with the associated clinical complications driven by portal hypertension (PH). PH may precede fibrosis development, probably due to endothelial dysfunction at early stages of the disease. Our aim was to characterize liver sinusoidal endothelial cell (LSEC) dedifferentiation/capillarization and its contribution to PH in NASH, together with assessing statins capability to revert endothelial function improving early NASH stages. Sprague-Dawley rats were fed with high fat glucose-fructose diet (HFGFD), or control diet (CD) for 8 weeks and then treated with simvastatin (sim) (10 mg·kg·day), atorvastatin (ato) (10 mg·kg·day) or vehicle during 2 weeks. Biochemical, histological and hemodynamic determinations were carried out. Sinusoidal endothelial dysfunction was assessed in individualized sorted LSEC and hepatic stellate cells (HSC) from animal groups and in whole liver samples. HFGFD rats showed full NASH features without fibrosis but with significantly increased portal pressure compared with CD rats (10.47 ± 0.37 mmHg vs 8.30 ± 0.22 mmHg; p < 0.001). Moreover, HFGFD rats showed a higher percentage of capillarized (CD32b/CD11b) LSEC (8% vs 1%, p = 0.005) showing a contractile phenotype associated to HSC activation. Statin treatments caused a significant portal pressure reduction (sim: 9.29 ± 0.25 mmHg, p < 0.01; ato: 8.85 ± 0.30 mmHg, p < 0.001), NASH histology reversion, along with significant recovery of LSEC differentiation and a regression of HSC activation to a more quiescent phenotype. In an early NASH model without fibrosis with PH, LSEC transition to capillarization and HSC activation are reverted by statin treatment inducing portal pressure decrease and NASH features improvement.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients

  • Ventura-Cots, Meritxell
  • Carmona, Isabel
  • Moreno, Carolina
  • Ampuero, Javier
  • Simón-Talero, Macarena
  • Sanpedro, Francesc
  • Les Bujanda, Íñigo
  • Romero-Gómez, Manuel
  • Genescà, Joan
Background: Episodes of hepatic encephalopathy (HE) have been related to low survival rate. However, the relation between its clinical evolution and mortality has not been assessed. Methods: A retrospective analysis of 245 cirrhotic patients admitted for an acute episode of HE (⩾grade 2) or who developed an HE episode after an upper gastrointestinal bleeding (UGIB) event was performed to assess the relation between time in HE and transplant-free survival. Results: Median (IQR25–75) time in HE was 48 h (24–96 h) in the whole cohort. Patients who presented a longer time in HE (>48 h; n = 89) exhibited a lower transplant-free survival at 28 days (67.2% versus 88.9%, p < 0.001), 90 days (48.7% versus 73.8%, p < 0.001) and 365 days (30.3% versus 53.2%, p < 0.001), as compared to those with less time in HE (⩽48 h; n = 156). Survival rates remained significantly different, with lower percentages in the group with time in HE >48 h, when comparing patients according to baseline HE grade (2 versus ⩾3) or model for end-stage liver disease (MELD) function (⩽15 versus >15). Time in HE was also an independent risk factor for mortality at each time point, hazard ratio (HR) (95 CI%) 28 days 2.59 (1.39–4.84); 90 days 1.98 (1.28–3.1) and 365 days 1.5 (1.08–2.19). Conclusions: The duration of the acute HE episode determines survival in cirrhotic patients independently of liver function and baseline HE grade., MST is a recipient of a Río Hortega grant from Instituto de Salud Carlos III, Spain. JG is a recipient of a Research Intensification grant from Instituto de Salud Carlos III, Spain. MVC is a recipient of a scholarship grant for study extension abroad, sponsored by the Spanish Association for the Study of the Liver. The study was partially funded by grants PI14/00331 and PI15/00066 from Instituto de Salud Carlos III, Spain and co-funded by European Union (ERDF/ESF, 'Investing in your future'). CIBERehd is supported by Instituto de Salud Carlos III, Spain.